NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market Tuesday a 17 percent year-over-year increase in its revenues driven by its hereditary cancer tests.

For the three months ended March 31, Myriad reported total revenues of $182.9 million, up from $156.5 million in the third quarter of fiscal year 2013. The firm easily beat the consensus analysts' estimate of $175.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.